Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

Virtual Investor Update
June 1, 2022
Today’s agenda

Brief introduction
Lloyd M. Segal – President & CEO, Repare Therapeutics

Transaction overview & financial terms
Kim Seth – EVP & Head of Business and Corporate Development
Steve Forte – EVP & CFO

Strategic perspective
Lloyd M. Segal – President & CEO, Repare Therapeutics

Q&A
Repare participants on today’s call

Lloyd M. Segal  
President & CEO

Kim Seth, PhD  
EVP & Head of Business  
and Corporate Development

Steve Forte  
Chief Financial Officer
Disclaimer

Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and securities law in Canada. Words such as "anticipates," "believes," "expects," “intends,” “plans,” “potential,” “projects,” “would” and “future” or similar expressions are intended to identify forward-looking statements. Each of these forward-looking statements involves substantial risks and uncertainties that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding the initiation, timing, progress and results of our current and future preclinical studies and clinical trials, including specifically our clinical trials of RP-3500 and RP-6306; the expected timing of program updates and data disclosures; the timing of filing INDs and other regulatory documents, including the initiation of IND-enabling studies for our PolO inhibitor program; the timing and likelihood of seeking regulatory approval for our product candidates; the competitive landscape for our product candidates; our ability to identify and develop additional product candidates using our SNIPRx platform; and our estimates regarding expenses, future revenue, capital requirements, cash runway and needs for additional financing.

These forward-looking statements reflect our current beliefs and expectations. Many factors may cause differences between current expectations and actual results, including the duration and impact of the ongoing COVID-19 pandemic and the evolving situation regarding the Omicron variant of COVID-19 on our business and market volatility, unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and unexpected litigation or other disputes. These and other risks are described more fully in our filings with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC and the AMF on March 1, 2022, and other documents we subsequently filed with or furnished to the SEC and the AMF, and its other documents subsequently filed with or furnished to the SEC and AMF, including the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 5, 2022. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Solely for convenience, the trademarks and trade names in this presentation may be referred to without the * and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.
An overview of Camonsertib

Camonsertib is an oral ATR inhibitor to treat cancers with DNA Damage Response (“DDR”) defects and high replication stress. Developed entirely in-house at Repare.

Repare initiated the first in-human trial for camonsertib in July 2020.

ATR is a critical DDR protein with a central role in regulation of replication stress.

Clinical validation of ATR/ATM SL relationship demonstrated at ASCO 2019 and further validated by Repare at AACR-NCI-EORTC in October 2021 and at AACR in April 2022.
**Camonsertib: Potential best-in-class ATR inhibitor**

Ph1/2 monotherapy trial demonstrated proof of concept in ovarian cancer

- **25%** overall response (5/20*)
- **35w** median PFS
- **75%** CBR
- **90%** (18/20) of patients had prior PARPi
- **85%** (17/20) of patients were platinum refractory/resistant*

<table>
<thead>
<tr>
<th>Done</th>
<th>In progress</th>
<th>Future</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+ PARPi</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**Compelling rationale for ATRi combination therapy with PARPi, radiotherapy and PD-1/L1.**

**Potential for best-in-class in terms of safety, potency and selectivity.**

**Proprietary patient selection insights to expand addressable patient populations.**

*Platinum refractory/resistant: progression on platinum or a platinum-free interval of <6 mo. CBR: OR or ≥16w on therapy without progression
Transaction overview

Long-term, global camonsertib collaboration with U.S. co-development, profit/cost share and co-promotion option

**REPA RE THERAPEUTICS**
- Potential best-in-class ATRi
- Potential for multiple combinations
- Compelling clinical data across tumors & backgrounds
- Leader in synthetic lethality

**Roche**
- Unique expertise in precision oncology
- Global reach and footprint
- Track record of success
- Shared, ambitious vision for the asset

Camonsertib
Financial terms

**Upfront**
- $125M

**Milestones**
- $55M near-term
- $1.2B Total

**U.S. Development, Profit/Cost & Co‐promotion option**
- Partnership
  - 50/50 US co-development & profit share & U.S. Co-promotion
  - Milestone payments

**Royalties**
- High single-digit to high-teens
Financial implications

Transaction subject to U.S antitrust review and customary conditions. Expected to close in Q3.

Cash runway extended into 2026.
Summary

Unique expertise in precision oncology
Global reach and footprint
Track record of success
Shared, ambitious vision for the asset
Robust pipeline of SL-based precision oncology therapeutics

<table>
<thead>
<tr>
<th>SL Pair</th>
<th>Tumor lesion</th>
<th>Drug target</th>
<th>Discovery</th>
<th>IND-Enabling</th>
<th>Phase 1/2</th>
<th>Registration-directed</th>
<th>Anticipated milestones</th>
<th>Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical</strong></td>
<td>ATR inhibitor RP-3500</td>
<td>ATM + 16 STEP² lesions</td>
<td>ATR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>PKMYT1 inhibitor RP-6306</td>
<td>CCNE1, FBXW7 + others</td>
<td>PKMYT1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Repare Therapeutics</td>
</tr>
<tr>
<td><strong>Preclinical</strong></td>
<td>Polθ inhibitor</td>
<td>BRCA1/2 + others</td>
<td>Polθ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ono</td>
</tr>
<tr>
<td><strong>Discovery</strong></td>
<td>SNIPRx® platform</td>
<td>Multiple additional SL targets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Repare Therapeutics</td>
</tr>
</tbody>
</table>

Discovery and validation of new SL precision oncology targets
Strategic perspective on this partnership

- Validates the strength of our SNIPRx and STEP² platform and approach, our discovery and early clinical development and capabilities.

- Further strengthens our balance sheet and adds two additional years of runway – funding the company into 2026.

- Provides a vastly expanded ability to develop and commercialize camonsertib more rapidly and on a global scale.

- Allows greater focus on exciting opportunities across our pipeline with RP-6306, Polθ, a new expected IND-enabling program start in H1 2023 and a compelling pipeline of earlier stage assets.
Q&A Session